{"created":"2023-05-15T16:32:16.533023+00:00","id":4054,"links":{},"metadata":{"_buckets":{"deposit":"750059b8-39dc-40ed-b4aa-47aa0921f0e9"},"_deposit":{"created_by":2,"id":"4054","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"4054"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00004054","sets":["73:74"]},"author_link":["16172","16173"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-02-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"61","bibliographicPageStart":"40","bibliographicVolumeNumber":"8","bibliographic_titles":[{"bibliographic_title":"Pharmaceuticals"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Pharmaceuticals, 8(1), pp.40-61; 2015","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Multidisciplinary Digital Publishing Institute (MDPI)"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/ph8010040","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/)."}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"14248247","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kobayashi, Hirohito"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tanaka, Yoshimasa"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"Pharma8_40.pdf","filesize":[{"value":"796.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Pharma8_40.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/4054/files/Pharma8_40.pdf"},"version_id":"13d669d0-a4af-4aa6-b6ca-81fc2b3d2dcb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Cancer immunotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"Nitrogen-containing bisphosphonate","subitem_subject_scheme":"Other"},{"subitem_subject":"Phosphoantigen","subitem_subject_scheme":"Other"},{"subitem_subject":"Tumor","subitem_subject_scheme":"Other"},{"subitem_subject":"Vγ9Vδ2 T cell","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"γδ T Cell Immunotherapy?A Review","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"γδ T Cell Immunotherapy?A Review"}]},"item_type_id":"2","owner":"2","path":["74"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-03-31"},"publish_date":"2015-03-31","publish_status":"0","recid":"4054","relation_version_is_last":true,"title":["γδ T Cell Immunotherapy?A Review"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:26:30.739803+00:00"}